Condition
Mesothelioma
Estimated Enrollment: 40
Age Group: 18 Years and older (Adult, Senior)
Gender: All
Study Type: Interventional
Study Design Allocation: Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment
Study ID Numbers: UPCC 02510; 811318
Study First Received: May 6, 2010
Last Updated: October 10, 2016
Estimated Primary Completion Date: October 2013
Primary Outcome Measures:
To determine the safety of administering intrapleural SCH 721015, Ad.hIFN-alpha2b (Adenoviral-mediated Interferon-alpha) in combination with chemotherapy for the management of MPM.|To estimate objective response rates and distribution|Time to Progression
Sponsors and Collaborators:
Abramson Cancer Center of the University of Pennsylvania
Website Link: https://ClinicalTrials.gov/show/NCT01119664
